Only members with restricted access (ie. academics, asset owners, government and regulatory, independent advisers/trustees and sponsoring employers) can view this article. Please login or join to view.

Claire Jervis looks at the healthcare sector and the reasons behind its challenging performance. She discusses the impact of Trump's policies on pharmaceutical companies and how Foresight Group's portfolio is positioned to nagivate this difficult geopolitical environment.

To the extent that anything on this website constitutes a financial promotion it is exempt from the general prohibition in S21 of FSMA on the basis that the site is only intended for investment professionals as such term is defined in S19 of the Financial Promotions Order. Please note that Pensions for Purpose does not provide consultancy services, advice or personal recommendations on any of the investment opportunities mentioned on the platform. We curate content written by members and do not endorse any underlying funds.

Learn more here

Phone:
Finance: 01234 388845
Events: 0330 223 6152

Email:
Event enquiries
Finance enquiries
General enquiries
Membership enquiries
Press enquiries
Training enquiries

Address:
11 Phillips Close
Headley
Hampshire
GU35 8LY

Pensions for Purpose acts as an information centre only. We do not endorse any content published on this website that originated from one of our members. For more information, please see the website terms of use

Sign up to our newsletters

Sign up to receive email updates, including newsletters, event invitations, research briefings, and policy or community news. You can update your preferences at any time.

Email address

First name

Last name

Company name

Required fields

We handle your data with care. See our privacy policies for full details.

Website Terms | Acceptable Use Policy and Content Rules | Privacy and Cookies Policy

Pulse check: the tenuous state of global pharma – Foresight Group

If you’ve been following Foresight Group's commentary over the last year, you’ll know that their holdings in the healthcare sector – in particular, pharma companies and their suppliers – have experienced challenging performance.

Only members with restricted access (ie. academics, asset owners, government and regulatory, independent advisers/trustees and sponsoring employers) can view this article. Please login or join to view.

Sign up to our newsletters